Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib

To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.

Trial Details

NCT ID
NCT06817720
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • olverembatinib
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Early chronic phase: time from diagnosis to therapy ≤ 12 months.
  • Late chronic phase: time from diagnosis to therapy \> 12 months.
  • Blastic phase: presence of 30% blasts or more in the peripheral blood or bone marrow.
  • Accelerated phase CML: presence of any of the following features:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →